Dysregulated lipid metabolism links NAFLD to cardiovascular disease

[1]  F. Pattou,et al.  Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. , 2020, Gastroenterology.

[2]  G. Silecchia,et al.  Relationship between hepatic and systemic angiopoietin‐like 3, hepatic Vitamin D receptor expression and NAFLD in obesity , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[3]  F. V. van’t Hooft,et al.  Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids , 2020, Journal of Lipid Research.

[4]  A. Hollenberg,et al.  Thyroid Hormone Signaling and the Liver , 2020, Hepatology.

[5]  J. Borén,et al.  Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance , 2020, Nature Communications.

[6]  K. Clément,et al.  Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort. , 2020, Journal of hepatology.

[7]  R. Schwabe,et al.  Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis. , 2020, Cell metabolism.

[8]  T. Hassanein,et al.  Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. , 2020, Journal of hepatology.

[9]  B. Nordestgaard,et al.  Contribution of remnant cholesterol to cardiovascular risk , 2020, Journal of internal medicine.

[10]  K. Petersen,et al.  Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease , 2020, Proceedings of the National Academy of Sciences.

[11]  Tom M Palmer,et al.  Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis , 2020, PLoS medicine.

[12]  V. Wong,et al.  Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial , 2020, Hepatology.

[13]  C. Ruhl,et al.  Patatin‐Like Phospholipase Domain‐Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population , 2020 .

[14]  Shelly C. Lu,et al.  Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. , 2020, Cell metabolism.

[15]  J. Schattenberg,et al.  Metabolic inflammation - a role for hepatic inflammatory pathways as driver of comorbidities in non-alcoholic fatty liver disease (NAFLD)? , 2020, Gastroenterology.

[16]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[17]  C. Byrne,et al.  Complications, morbidity and mortality of nonalcoholic fatty liver disease. , 2020, Metabolism: clinical and experimental.

[18]  G. Vilahur,et al.  Advances in HDL: Much More than Lipid Transporters , 2020, International journal of molecular sciences.

[19]  H. Krumholz,et al.  Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses , 2019, BMJ.

[20]  E. Guallar,et al.  Non‐alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study , 2019, Journal of gastroenterology and hepatology.

[21]  G. Marchesini,et al.  Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  B. Neuschwander‐Tetri,et al.  Impact of Obeticholic Acid on the Lipoprotein Profile in Patients with Nonalcoholic Steatohepatitis. , 2020, Journal of hepatology.

[23]  F. Violi,et al.  Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  H. Kauma,et al.  Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study) , 2019, Scandinavian journal of clinical and laboratory investigation.

[25]  Yu Xu,et al.  Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non‐invasive score , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[26]  C. Sirlin,et al.  Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. , 2019, The Journal of clinical investigation.

[27]  Manfred von der Ohe,et al.  Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial , 2019, The Lancet.

[28]  Monica A. Tincopa,et al.  Evaluation of Dietary Approaches for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review , 2019, Nutrients.

[29]  C. Ruhl,et al.  Patatin‐Like Phospholipase Domain‐Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population , 2020, Hepatology.

[30]  A. Prat,et al.  Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice , 2019, JHEP reports.

[31]  B. Neuschwander‐Tetri,et al.  Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2019, The Lancet.

[32]  Jonathan D. Smith,et al.  HDL Flux is Higher in Patients with Nonalcoholic Fatty Liver Disease. , 2019, American journal of physiology. Endocrinology and metabolism.

[33]  E. Schiff,et al.  CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[34]  Reiko Ohmori,et al.  Plasma Betatrophin Levels and Carotid Atherosclerosis , 2019, Disease markers.

[35]  S. Msika,et al.  Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study. , 2019, The lancet. Diabetes & endocrinology.

[36]  P. Galle,et al.  Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low‐Density Lipoprotein Cholesterol , 2019, Hepatology communications.

[37]  L. Hodson,et al.  The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state , 2019, Nature Reviews Endocrinology.

[38]  M. Kattan,et al.  Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity. , 2019, JAMA.

[39]  N. Lundbom,et al.  Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. , 2019, JCI insight.

[40]  P. Libby,et al.  Atherosclerosis , 2019, Nature Reviews Disease Primers.

[41]  M. Budoff,et al.  Nonalcoholic Fatty Liver Disease Is Associated With Arterial Distensibility and Carotid Intima-Media Thickness: (from the Multi-Ethnic Study of Atherosclerosis). , 2019, The American journal of cardiology.

[42]  Youren Chen,et al.  Correlation of triglyceride to high-density lipoprotein cholesterol ratio with nonalcoholic fatty liver disease among the non-obese Chinese population with normal blood lipid levels: a retrospective cohort research , 2019, Lipids in Health and Disease.

[43]  Yan Liu,et al.  Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis , 2019, Scientific Reports.

[44]  F. Pattou,et al.  Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients , 2019, BMC Medical Genomics.

[45]  S. Fleury,et al.  Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution , 2019, Nature Metabolism.

[46]  I. Benseñor,et al.  Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil. , 2019, Atherosclerosis.

[47]  R. Krauss,et al.  Relationship between resolution of non‐alcoholic steatohepatitis and changes in lipoprotein sub‐fractions: a post‐hoc analysis of the PIVENS trial , 2019, Alimentary pharmacology & therapeutics.

[48]  N. Seidah,et al.  Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice , 2019, The Journal of Biological Chemistry.

[49]  J. Trotter,et al.  NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis , 2019, Hepatology.

[50]  M. Connelly,et al.  Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. , 2019, Journal of hepatology.

[51]  Walid Kamal Abdelbasset,et al.  A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease , 2019, Medicine.

[52]  A. Isaacs,et al.  Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and Coronary Artery Disease , 2019, Hepatology communications.

[53]  R. M. Learned,et al.  Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis , 2019, Journal of Lipid Research.

[54]  D. Vance,et al.  Impaired Hepatic Phosphatidylcholine Synthesis Leads to Cholestasis in Mice Challenged With a High‐Fat Diet , 2019, Hepatology communications.

[55]  B. Neuschwander‐Tetri,et al.  Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial , 2018, The Lancet.

[56]  M. Criqui,et al.  The association between liver fat and systemic calcified atherosclerosis. , 2019, Journal of vascular surgery.

[57]  Á. González-Rodríguez,et al.  Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis. , 2018, The American journal of pathology.

[58]  S. Wild,et al.  Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study , 2018, Gut.

[59]  J. Hecksher-Sørensen,et al.  The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways , 2018, JACC. Basic to translational science.

[60]  R. Loomba,et al.  GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[61]  F. Violi,et al.  Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease , 2018, Journal of clinical medicine.

[62]  Min-Sun Kwak,et al.  Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter , 2018, Journal of Gastroenterology.

[63]  Z. Younossi,et al.  Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality , 2018, Hepatology communications.

[64]  Claudio Aguayo,et al.  Association between insulin resistance and the development of cardiovascular disease , 2018, Cardiovascular Diabetology.

[65]  Guidong Xu,et al.  Fibroblast growth factor 21 inhibits atherosclerosis in apoE−/− mice by ameliorating Fas-mediated apoptosis , 2018, Lipids in Health and Disease.

[66]  F. Jornayvaz,et al.  Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives , 2018, Endocrine reviews.

[67]  Xingquan Zhao,et al.  Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old , 2018, BMC Cardiovascular Disorders.

[68]  J. O’Keefe,et al.  Association of Hepatic Steatosis With Subclinical Atherosclerosis: Systematic Review and Meta‐Analysis , 2018, Hepatology communications.

[69]  M. Friedrich-Rust,et al.  Patatin‐like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events , 2018, Hepatology communications.

[70]  H. Guillou,et al.  The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity , 2018, Nature Communications.

[71]  A. Jaeschke,et al.  Low-density lipoprotein receptor–related protein-1 dysfunction synergizes with dietary cholesterol to accelerate steatohepatitis progression , 2018, The Journal of Biological Chemistry.

[72]  B. Nordestgaard,et al.  Antiplatelet therapy: Pharmacogenomic approach to tailor drug therapy , 2018, Nature Reviews Cardiology.

[73]  Xi-Long Zheng,et al.  Lipoprotein lipase: Biosynthesis, regulatory factors, and its role in atherosclerosis and other diseases. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[74]  T. Lehtimäki,et al.  NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects , 2018, Human molecular genetics.

[75]  J. Trotter,et al.  NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2018, The Lancet.

[76]  Jens Nielsen,et al.  An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans. , 2018, Cell metabolism.

[77]  J. Binet,et al.  Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. , 2018, Journal of medicinal chemistry.

[78]  B. Nordestgaard,et al.  Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals , 2018, European heart journal.

[79]  Weijian Ke,et al.  Angiopoietin‐like protein 8/betatrophin correlates with hepatocellular lipid content independent of insulin resistance in non‐alcoholic fatty liver disease patients , 2018, Journal of diabetes investigation.

[80]  W. Wahli,et al.  Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[81]  Byung Gyu Kim,et al.  Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study. , 2017, Journal of hepatology.

[82]  K. Cusi,et al.  Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[83]  K. Kalinov,et al.  Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis , 2017, Diabetology & Metabolic Syndrome.

[84]  Y. van der Graaf,et al.  Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials , 2017, Cardiovascular Diabetology.

[85]  Raquel S. Sevilla,et al.  Exome-wide association study of plasma lipids in >300,000 individuals , 2017, Nature Genetics.

[86]  H. Häring,et al.  Fibroblast Growth Factor 21—Metabolic Role in Mice and Men , 2017, Endocrine reviews.

[87]  S. Hunt,et al.  Weight and Metabolic Outcomes 12 Years after Gastric Bypass , 2017, The New England journal of medicine.

[88]  D. Vance,et al.  The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. , 2017, Biochimica et biophysica acta. Biomembranes.

[89]  K. Cusi,et al.  Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial , 2017, The Journal of clinical endocrinology and metabolism.

[90]  S. Milstein,et al.  Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. , 2017, Cell metabolism.

[91]  Jiandie D. Lin,et al.  Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity , 2017, The Journal of clinical investigation.

[92]  A. Orekhov,et al.  Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases , 2017, Oxidative medicine and cellular longevity.

[93]  B. Staels,et al.  Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia and NAFLD. , 2017 .

[94]  E. Paschetta,et al.  Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis , 2017, JAMA internal medicine.

[95]  M. Fukui,et al.  Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease , 2017, Medicine.

[96]  B. Finck,et al.  PPARs and nonalcoholic fatty liver disease. , 2017, Biochimie.

[97]  J. Eeckhoute,et al.  Distinct but complementary contributions of PPAR isotypes to energy homeostasis. , 2017, The Journal of clinical investigation.

[98]  J. Danesh,et al.  ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. , 2017, Journal of the American College of Cardiology.

[99]  A. Isaacs,et al.  PNPLA3, TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease. , 2017, Gastroenterology.

[100]  Z. Mo,et al.  Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males , 2017, The American journal of the medical sciences.

[101]  Sungeun Kim,et al.  Association between vascular inflammation and non-alcoholic fatty liver disease: Analysis by 18F-fluorodeoxyglucose positron emission tomography. , 2017, Metabolism: clinical and experimental.

[102]  J. Yamauchi,et al.  APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice* , 2017, The Journal of Biological Chemistry.

[103]  E. Paschetta,et al.  Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges , 2016, Hepatology.

[104]  G. Silecchia,et al.  The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis , 2017, The Journal of pediatrics.

[105]  K. Cusi,et al.  Reply to "statins and non-alcoholic steatohepatitis". , 2017, Metabolism: clinical and experimental.

[106]  Yingying Ding,et al.  Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis , 2016, Scientific Reports.

[107]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[108]  J. Lima,et al.  Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study , 2016, Gut.

[109]  S. Klein,et al.  VLDL Triglyceride Kinetics in Lean, Overweight, and Obese Men and Women. , 2016, The Journal of clinical endocrinology and metabolism.

[110]  Corrado Barbui,et al.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. , 2016, Journal of hepatology.

[111]  G. Kemp,et al.  Exercise Training Reduces Liver Fat and Increases Rates of VLDL Clearance But Not VLDL Production in NAFLD. , 2016, The Journal of clinical endocrinology and metabolism.

[112]  J. Gugenheim,et al.  Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis , 2016, Front. Physiol..

[113]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[114]  J. Hardies,et al.  Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus , 2016, Annals of Internal Medicine.

[115]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[116]  P. Magni,et al.  Liver fat accumulation is associated with circulating PCSK9 , 2016, Annals of medicine.

[117]  Dermot F. Reilly,et al.  The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. , 2016, Gastroenterology.

[118]  Philippe Lehert,et al.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.

[119]  Q. Pan,et al.  APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases , 2016, Digestive Diseases and Sciences.

[120]  E. Kang,et al.  Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies , 2016, Scientific Reports.

[121]  Alexander E. Lopez,et al.  Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. , 2016, The New England journal of medicine.

[122]  G. Gwak,et al.  The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. , 2016, Journal of clinical lipidology.

[123]  D. Tanné,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[124]  Eijiro Watanabe,et al.  Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-alcoholic steatohepatitis , 2016, Scientific Reports.

[125]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[126]  B. Staels,et al.  Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. , 2016, Annual review of physiology.

[127]  K. Cusi,et al.  Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. , 2016, The Journal of clinical endocrinology and metabolism.

[128]  Yuan Zhang,et al.  Angiopoietin-like protein 8 (betatrophin) is a stress-response protein that down-regulates expression of adipocyte triglyceride lipase. , 2016, Biochimica et biophysica acta.

[129]  G. Ioannou.  The Role of Cholesterol in the Pathogenesis of NASH , 2016, Trends in Endocrinology & Metabolism.

[130]  S. B. Pedersen,et al.  Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease. , 2016, The Journal of clinical endocrinology and metabolism.

[131]  S. Sookoian,et al.  The dual and opposite role of the TM6SF2‐rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta‐analysis , 2015, Hepatology.

[132]  P. Senthilnathan,et al.  The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: "NASHOST" prospective observational trial. , 2015, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[133]  P. Paschos,et al.  Nonalcoholic fatty liver disease and statins. , 2015, Metabolism: clinical and experimental.

[134]  N. Lundbom,et al.  Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[135]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[136]  F. Pattou,et al.  Bariatric surgery, lipoprotein metabolism and cardiovascular risk , 2015, Current opinion in lipidology.

[137]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[138]  E. van Marck,et al.  PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. , 2015, Journal of hepatology.

[139]  A. Xu,et al.  Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice , 2015, Circulation.

[140]  S. Hyun,et al.  Association Between Nonalcoholic Fatty Liver Disease and Carotid Artery Inflammation Evaluated by 18F-Fluorodeoxyglucose Positron Emission Tomography , 2015, Angiology.

[141]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[142]  M. Orho-Melander,et al.  Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. , 2015, Journal of hepatology.

[143]  O. Cummings,et al.  NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non‐HDL‐C levels , 2015, Alimentary pharmacology & therapeutics.

[144]  J. Borén,et al.  Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease , 2015, Hepatology.

[145]  R. McCuskey,et al.  Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. , 2014, Journal of hepatology.

[146]  F. Pattou,et al.  Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease: A 5-Year Controlled Longitudinal Study , 2014, Annals of surgery.

[147]  B. Nordestgaard,et al.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.

[148]  He Zhang,et al.  Loss-of-function mutations in APOC3, triglycerides, and coronary disease. , 2014, The New England journal of medicine.

[149]  Y. Xin,et al.  Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population. , 2014, World journal of gastroenterology.

[150]  He Zhang,et al.  Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk , 2014, Nature Genetics.

[151]  J. Browning,et al.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.

[152]  Anne Tybjærg-Hansen,et al.  Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease , 2014, Nature Genetics.

[153]  M. Taskinen,et al.  A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population , 2013, Obesity.

[154]  Y. Bao,et al.  Serum Levels of Fibroblast Growth Factor 19 Are Inversely Associated with Coronary Artery Disease in Chinese Individuals , 2013, PloS one.

[155]  A. de Roos,et al.  Overexpression of Angiopoietin-Like Protein 4 Protects Against Atherosclerosis Development , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[156]  B. Nordestgaard,et al.  Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.

[157]  Hanno Pijl,et al.  GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice , 2012, PloS one.

[158]  D. Brenner,et al.  Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial , 2012, Hepatology.

[159]  Robert V Farese,et al.  Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. , 2012, Cell metabolism.

[160]  F. Eren,et al.  Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. , 2012, Clinical biochemistry.

[161]  N. Lundbom,et al.  Genetic variation in PNPLA3 but not APOC3 influences liver fat in non‐alcoholic fatty liver disease , 2012, Journal of gastroenterology and hepatology.

[162]  W. Jia,et al.  Low Level of Low-Density Lipoprotein Receptor-Related Protein 1 Predicts an Unfavorable Prognosis of Hepatocellular Carcinoma after Curative Resection , 2012, PloS one.

[163]  A. Miyazaki,et al.  Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice , 2011, Diabetologia.

[164]  R. Krauss,et al.  MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. , 2011, The Journal of clinical endocrinology and metabolism.

[165]  G. López,et al.  Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome? , 2011, Clinica chimica acta; international journal of clinical chemistry.

[166]  M. Taskinen,et al.  Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[167]  Udo Hoffmann,et al.  Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits , 2011, PLoS genetics.

[168]  O. Cummings,et al.  Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. , 2010, Gastroenterology.

[169]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[170]  K. Petersen,et al.  Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[171]  P. Giral,et al.  Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.

[172]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[173]  E. Ulukaya,et al.  Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance , 2009, European journal of gastroenterology & hepatology.

[174]  P. Talmud,et al.  Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. , 2009, Atherosclerosis.

[175]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[176]  O. Hamdy,et al.  The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. , 2008, Journal of the American College of Cardiology.

[177]  Alberto Zambon,et al.  Fibrates and future PPARα agonists in the treatment of cardiovascular disease , 2008, Nature Clinical Practice Cardiovascular Medicine.

[178]  Philippe Giral,et al.  Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.

[179]  Martin Adiels,et al.  Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[180]  B. S. Mohammed,et al.  Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. , 2008, Gastroenterology.

[181]  D. Vance,et al.  The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. , 2006, Cell metabolism.

[182]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[183]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[184]  Alfonso T. Perez,et al.  A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. , 2005, Diabetes care.

[185]  J. Jukema,et al.  Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol. , 2004, Blood.

[186]  Y. Momose,et al.  Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. , 2000, Biochemical and biophysical research communications.

[187]  Michael J. Thomas,et al.  Molecular Distinction of Phosphatidylcholine Synthesis between the CDP-Choline Pathway and Phosphatidylethanolamine Methylation Pathway* , 1999, The Journal of Biological Chemistry.

[188]  R. Wootton,et al.  Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[189]  J. McGarry,et al.  Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. , 1978, The Journal of biological chemistry.